Boston Scientific (NYSE:BSX) Director Edward Ludwig Buys 3,580 Shares

Boston Scientific Corporation (NYSE:BSX) Director Edward Ludwig acquired 3,580 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the purchase, the director owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. This represents a 16.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Boston Scientific Price Performance

Shares of Boston Scientific stock traded up $0.41 on Thursday, hitting $57.08. The company had a trading volume of 12,837,051 shares, compared to its average volume of 16,615,801. The business has a 50-day simple moving average of $62.46 and a 200-day simple moving average of $80.71. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The company has a market cap of $84.84 billion, a PE ratio of 23.88, a PEG ratio of 1.04 and a beta of 0.62. Boston Scientific Corporation has a 52 week low of $52.52 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business’s revenue was up 11.6% on a year-over-year basis. During the same period last year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Research analysts expect that Boston Scientific Corporation will post 3.38 EPS for the current fiscal year.

Boston Scientific declared that its board has initiated a stock repurchase plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Murphy & Mullick Capital Management Corp boosted its position in shares of Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the period. FWL Investment Management LLC acquired a new position in shares of Boston Scientific in the 2nd quarter valued at $26,000. Swiss RE Ltd. acquired a new position in shares of Boston Scientific in the 4th quarter valued at $26,000. Garton & Associates Financial Advisors LLC acquired a new position in shares of Boston Scientific in the 4th quarter valued at $26,000. Finally, United Community Bank boosted its position in shares of Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 147 shares during the period. Institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Robert W. Baird dropped their price objective on Boston Scientific from $78.00 to $75.00 and set an “outperform” rating on the stock in a research note on Tuesday. Mizuho dropped their price objective on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating on the stock in a research note on Monday, April 13th. Weiss Ratings downgraded Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Oppenheimer set a $90.00 price objective on shares of Boston Scientific in a research report on Thursday, April 23rd. Finally, Jefferies Financial Group reduced their price objective on shares of Boston Scientific from $110.00 to $100.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $92.71.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.